CJC-1295
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic growth hormone-releasing hormone analog, often built with a Drug Affinity Complex (DAC) that extends its half-life to days, marketed for body composition, sleep, recovery, and bone. It reliably raises growth hormone, but the clinical benefits remain speculative in humans. Safety is the gap: long-term data is thin, the long-acting form is hard to stop, and it can cause water retention and joint pain. Not an approved US drug and banned by WADA.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the natural signal your brain sends to the pituitary gland to produce growth hormone. It comes in two forms: CJC-1295 with DAC (Drug Affinity Complex), which binds to a blood protein called albumin giving it a 6-8 day half-life, and CJC-1295 without DAC (also called Modified GRF 1-29), which has a shorter ~30-minute half-life. Originally developed by ConjuChem Biotechnologies.
How it works in the body
Mimics growth hormone-releasing hormone (GHRH) by binding to GHRH receptors in your pituitary gland, signaling it to produce and release more growth hormone. With the DAC (Drug Affinity Complex) modification, it binds to albumin in your blood, extending its activity from minutes to days.
Research overview
CJC-1295 works by binding to GHRH receptors on the pituitary gland, triggering the natural signaling cascade that stimulates growth hormone production and release. A single injection of the DAC version can increase growth hormone levels 2-10 fold for 6 or more days, and raise IGF-1 (insulin-like growth factor 1) levels 1.5-3 fold for 9-11 days. Importantly, it preserves the body's natural pulsatile pattern of growth hormone release rather than producing a constant, unnatural elevation — a physiological finding that has not established greater clinical safety than direct growth hormone injections. The non-DAC version (Mod GRF 1-29) is often preferred in wellness protocols because its shorter duration allows for more precise dosing control. Clinical data comes primarily from the DAC version's development program, which demonstrated sustained GH and IGF-1 elevation in human subjects. However, full Phase 3 clinical trials were never completed, and ConjuChem discontinued development.
Who researches CJC-1295?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People exploring sleep quality improvement
Researched for effects on sleep architecture, circadian rhythm, or sleep quality.
People researching bone health and density
Studied for effects on bone mineralization, fracture healing, or osteoporosis.
Important considerations for
Those with Active cancer
HighSustained GH elevation via GHRH mimicry may promote tumor growth.
Those with Pituitary tumors
AbsoluteDirectly stimulates pituitary GHRH receptors.
Those with Diabetic retinopathy
HighGH/IGF-1 axis activation can accelerate retinal damage.
Those who are pregnant or breastfeeding
AbsoluteNo safety data.
Safety & interactions
Do not use if
Pituitary tumors
AbsoluteDirectly stimulates pituitary GHRH receptors.
Active cancer
HighSustained GH elevation via GHRH mimicry may promote tumor growth.
Diabetic retinopathy
HighGH/IGF-1 axis activation can accelerate retinal damage.
General cautions
Pregnancy
AbsoluteNo safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
One Phase II death was reported; coronary artery disease was considered the likely explanation, with drug causality unresolved.
Lowaidsmap (Jul 2006); ClinicalTrials.gov NCT00267527
Long-term safety data beyond a few months is lacking
HighPMID 16352683; program discontinued 2006
DAC version half-life 6-8 days cannot quickly discontinue if adverse reaction
ModeratePMID 16352683 (half-life 5.8-8.1 days)
Water retention (hands, feet, face)
ModerateGH/IGF-1 pharmacology (mechanism/class effect)
Potential GH-related side effects: joint pain, carpal tunnel, insulin resistance
ModerateGH-excess pharmacology (mechanism/class effect)
WADA banned
HighWADA Prohibited List S2.2 (growth hormone-releasing factors)
Interaction summary(6)
Rated by direction with this peptide
Insulin and other antidiabetic agents (insulin, sulfonylureas, metformin)
CautionModerateSustained GH elevation induces insulin resistance and can raise blood glucose, blunting glycemic control and potentially requiring antidiabetic dose adjustment.
GH/IGF-1 pharmacology; well-documented GH effect on glucose metabolism (acromegaly/GH-therapy data)
Glucocorticoids (corticosteroids)
CautionModerateGlucocorticoids suppress the GH/IGF-1 axis and blunt the pituitary GH response to GHRH, so they can reduce CJC-1295 efficacy while also compounding hyperglycemia.
Endocrine literature on glucocorticoid suppression of the GH axis (mechanism-based)
Somatostatin analogs (octreotide, lanreotide)
CautionModerateSomatostatin directly inhibits pituitary GH release and would antagonize or negate the GH secretion driven by CJC-1295.
GH physiology (somatostatin is the direct physiological brake on GH; mechanism-based)
GH secretagogues / ghrelin mimetics (Ipamorelin, GHRP-2/6, MK-677)
SynergisticModeratePairing a GHRH analog with a GHRP/ghrelin-mimetic produces supra-additive GH release via complementary mechanisms, which also amplifies GH-related side effects.
GHRH+GHRP synergy literature (multiple human studies at class level; mechanism-based)
Recombinant growth hormone (somatropin)
CautionTheoreticalCo-administration risks additive GH/IGF-1 excess; exogenous GH also raises somatostatin tone via negative feedback, which could paradoxically blunt the GHRH-driven response. Not studied in combination.
GH-axis negative feedback (mechanism-based; no combination trial)
Sex steroids (androgens / estrogens)
NeutralTheoreticalRelabeled from Synergistic to Neutral: the net effect is modulatory and mixed, not a unidirectional synergy or safety hazard. Sex-steroid priming (e.g., testosterone) augments GHRH-stimulated GH secretion, whereas oral estrogen LOWERS hepatic IGF-1 output (an opposing effect on the axis). This shifts response rather than adding risk.
GH-axis endocrinology (mechanism-based)
Known risks(6)
One death during a Phase II trial; coronary artery disease was reported as the likely explanation, but drug causality was not conclusively excluded.
Long-term safety data beyond a few months is lacking
DAC version half-life 6-8 days — cannot quickly discontinue effects if adverse reaction
Water retention (hands, feet, face)
Potential for GH-related side effects: joint pain, carpal tunnel, insulin resistance
WADA banned
Drug interactions(3)
Ipamorelin
Standard clinical combination. Different receptor pathways produce 3-5x GH release vs either alone.
GHRP-6
Similar synergy to ipamorelin but with more side effects (hunger, cortisol)
Somatostatin analogs
Would counteract GH-releasing effect
Research & benefits
Evidence base
- Evidence Level
- Phase 2 (Discontinued)
- Total Studies
- 8
- Human Studies
- 3
Foundational 2006 Teichman et al. RCT demonstrated dose-dependent GH/IGF-1 elevation. Ionescu 2006 confirmed preserved pulsatility. Development halted after Phase II death (attributed to pre-existing CAD). No further pharma-sponsored trials.
Researched for(7)
Rated by confidence in the evidence
Sustained GH elevation
HighHuman RCT showed GH rising 2 to 10x for 6+ days per injection, accumulating with repeat dosing.
PMID 16352683 (J Clin Endocrinol Metab 2006;91(3):799-805)
Preserved GH pulsatility
MediumHuman trial data indicate the natural GH pulse pattern is maintained, unlike exogenous GH.
PMID 17018654 (J Clin Endocrinol Metab 2006;91(12):4792-7)
Improved body composition
SpeculativePreliminary, based on the GH/IGF-1 rise promoting lipolysis and lean mass; no completed outcome trial.
Mechanistic extrapolation from GH/IGF-1 rise (PMID 16352683); lipodystrophy trial NCT00267527 halted 2006
Enhanced sleep quality
SpeculativePreliminary and mechanism-based; GHRH activity favors slow-wave sleep, with no CJC-1295 sleep studies.
Mechanism only (no CJC-1295-specific data)
Accelerated recovery
SpeculativePreliminary and mechanism-based; elevated GH/IGF-1 supports tissue repair, without CJC-1295-specific data.
Mechanism only (no CJC-1295-specific data)
Collagen/skin health
SpeculativePreliminary and mechanism-based; GH/IGF-1 signaling aids skin and connective tissue, no direct data.
Mechanism only (no CJC-1295-specific data)
Bone density support
SpeculativePreliminary; IGF-1 rise is shown, but the bone benefit is mechanism-based extrapolation only.
IGF-1 rise demonstrated (PMID 16352683); bone endpoint is mechanistic extrapolation
Benefits(8)
Sustained GH elevation
Preserved GH pulsatility
Improved body composition
Enhanced sleep quality
Accelerated recovery
Collagen/skin health
Bone density support
Synergy with Ipamorelin
Key studies(4)
Teichman SL et al.
J Clin Endocrinol Metab
2006
Dose-dependent GH 2-10x for 6+ days, IGF-1 1.5-3x for 9-11 days. Well tolerated.
Ionescu M, Frohman LA
J Clin Endocrinol Metab
2006
GH pulsatility preserved. Trough GH up 7.5x, total secretion up 46%.
Alba M et al.
Am J Physiol Endocrinol Metab
2006
Daily injections restored normal body weight and length in knockout mice
Sackmann-Sala L et al.
Growth Horm IGF Res
2009
Identified 5 serum biomarker changes linked to GH/IGF-1 activation
What research suggests over time
Weeks 2-4
Teichman et al. JCEM 2006Sustained GH and IGF-1 elevation is detectable in serum; improved sleep was not established in the cited trial.
Months 2-3
Practitioner-reportedImproved recovery, body composition shifts, and lean tissue maintenance in practitioner cohorts.
Long-term
Phase 1/2 trialsDose-dependent IGF-1 increases of up to 1.5-3× baseline sustained across multi-week dosing in published human studies.
Regulation & availability
Why researchers look at it
A single injection of the DAC version raises growth hormone levels 2-10 fold for six or more days and IGF-1 levels 1.5-3 fold for 9-11 days, preserving GH pulsatility, without demonstrated clinical safety superiority over synthetic GH. No Category 1 or other qualifying 503A bulk-compounding pathway has been identified for CJC-1295.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- CJC-1295 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024. Development reached Phase II before discontinuation in 2006.
- WADA status
- Banned — classified as GH secretagogue under prohibited substances
- Prescribability
- CJC-1295 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024. WADA prohibits it.
- Availability
- Some clinics and telehealth platforms advertise CJC-1295. These listings do not establish lawful bulk compounding: it is unapproved, is not in Category 1, and remains on FDA's nominated-but-withdrawn safety table. No FDA-approved retail product exists. WADA prohibits it.
International status
EU
Not approved
US
CJC-1295 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.
Australia
Schedule 4 via compounding with prescription
Regulatory timeline(3)
- 2006Phase I/II trials publishedTeichman and Ionescu studies in JCEM
- 2006Development haltedOne death in Phase II (attributed to pre-existing CAD). ConjuChem stopped development.
- 2023-09FDA Category 2Restricted from compounding
Sources & FAQs
Research sources(4)
Frequently asked questions(4)
DAC vs non-DAC?
DAC binds albumin for a 6-8 day half-life. Non-DAC (Mod GRF 1-29) has a half-life of about 30 minutes.
How long to see results?
Published trials establish GH and IGF-1 responses, but do not establish when sleep, energy or body-composition benefits occur.
Is it safe?
Well tolerated in trials at the doses studied. Reported effects include injection-site reactions, flushing and headache. FDA also identifies serious reactions involving increased heart rate and systemic vasodilation. One Phase II death attributed to pre-existing CAD. Long-term data lacking.
Legal in US 2026?
A prescription does not establish lawful compounding. CJC-1295 is unapproved and has no identified qualifying 503A bulk-compounding pathway. Some telehealth platforms advertise it. WADA prohibits it.